IOVA Q3 2022 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$100M

Net Income

-$100M

EPS (Diluted)

$-0.63

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$64M

Free Cash Flow

-$65M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$546M

Total Liabilities

$152M

Stockholders' Equity

$394M

Cash & Equivalents

$118M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$100M	-$86M	-16.4%
Net Income	-$100M	-$86M	-15.7%